CT-03 / Captor Therap - LARVOL DELTA

TARGETING MCL-1 WITH CARDIO-SAFE DEGRADER CT-03P EXERTS ACTIVITY IN AML AND OVERCOMES VENETOCLAX RESISTANCE (EHA 2026) - "Combination with venetoclax enhances CT-03p activities in venetoclax resistant and TP53-mutant AML cells and stem/progenitor cells. The importance of MCL-1 in therapy resistance and the lack of cardiotoxicity of CT-03p warrants future development of this degrader."

IO biomarker • Acute Myelogenous Leukemia • Hematological Malignancies • Leukemia • Mantle Cell Lymphoma • ANXA5 • CRBN

MITIGATING MCL-1-DRIVEN CARDIOTOXICITY: PRECLINICAL CHARACTERIZATION OF THE FIRST-IN-CLASS MCL-1 DEGRADER (EHA 2026) - "By achieving irreversible target depletion and demonstrating a superior safety pro(le in NHP models, our degrader represents a potent therapeutic strategy for relapsed/refractory AML. The compound is currently in IND/CTA-enabling studies, with a First-in-Human Phase 1 trial expected to commence by the end of 2026 to evaluate its ef(cacy as monotherapy and in combination with venetoclax."

First-in-human • Preclinical • Acute Myelogenous Leukemia • Cardiovascular • Hematological Malignancies • Leukemia • Mantle Cell Lymphoma • Solid Tumor • Targeted Protein Degradation • CRBN • MCL1

Preclinical evaluation of CT03: A cardiosafe, first-in-class bifunctional MCL1 degrader for the treatment of hematological malignancies. (ASCO 2026) - "CT-03 is a highly potent bifunctional MCL1 degrader that achieves complete target coverage and demonstrates a superior safety margin compared to traditional inhibitors. By reducing MCL1 levels rather than inducing compensatory elevation, CT03 mitigates the risk of cardiac adverse events. These results support the clinical potential of CT03 as a promising therapy for high-risk MDS and R/R AML."

First-in-human • Preclinical • Acute Myelogenous Leukemia • Hematological Malignancies • Myelodysplastic Syndrome • Oncology • Targeted Protein Degradation • BCL2 • MCL1

Preclinical evaluation of a cardiosafe first-in-class MCL-1 degrader for the treatment of hematological malignancies (AACR 2026) - "Combination with low-dose venetoclax (7.5 mpk) promoted tumor regression at 5 mpk using an intermittent dosing regimen (2 days on/5 days off)...These findings support MCL-1 degradation as a promising therapeutic approach for hematologic malignancies. The compound is advancing through IND/CTA-enabling studies, with a first-in-human Phase 1 trial planned for 2026."

First-in-human • Preclinical • Hematological Malignancies • Leukemia • Lung Cancer • Mantle Cell Lymphoma • Multiple Myeloma • Oncology • Solid Tumor • BCL2 • MCL1 • TNNI3

Captor Therapeutics Announces Three-Year Strategic Objectives (GlobeNewswire) - "Initiate the clinical development by Captor of its advanced projects CT-01 (Hepatocellular carcinoma) and CT-03 (haematological malignancies) in 2023 and 2024 respectively, with clinical data readouts in 2024 and 2025. Advance Captor's early pipeline assets in inflammation (CT-02, CT-05) to in-vivo proof of efficacy in 2023 as a prelude to collaborative development."

Clinical data • New trial • Preclinical • Gastrointestinal Cancer • Hematological Malignancies • Hepatocellular Cancer • Immunology • Leukemia • Liver Cancer • Oncology • Solid Tumor